Craig Halder, MBA

Chief Business Officer

Craig Halder joined Archon Biosciences as its chief business officer in early 2023, bringing a deep and diverse experience base in business development, commercialization, finance, strategy and operations.   

Prior to joining Archon, Craig led Life Sciences Research and Corporate & Business Development at Adaptive Biotechnologies, driving the application of immunogenomics into R&D programs across 100+ biopharma companies and research institutions and helping the company go public in 2019. Earlier in his career, he served in executive and senior leadership positions across the Novartis Group focusing on business development, M&A and commercialization of therapeutics spanning innovative pharmaceuticals to biosimilars and affordable generics. During this time, he led and supported two of Novartis’ largest acquisitions: The $1.5B acquisition of Fougera by Sandoz and the $50B integration of Alcon. He began his life sciences career in finance, strategy and product development roles at Amgen. 

Before his career in biotechnology, Craig served as a nuclear submarine officer in the US Navy and earned his Master of Business Administration with distinction from Harvard Business School and his bachelor’s degree with distinction in mechanical engineering from the US Naval Academy. 

---